LMRI

Lumexa (LMRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

RALEIGH, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging Holdings, Inc. (“Lumexa Imaging”) (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, announced today that Caitlin Zulla, CEO, and Tony Martin, CFO, will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference, held in Boston, including a fireside chat at 3:00 PM ET and one-on-one meetings with Caitlin Zulla and Tony Martin on September 9, 2026.

The consensus price target hints at a 36.9% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 Earnings Call Transcript

Lumexa Imaging NASDAQ: LMRI reported second-quarter revenue growth, higher advanced-imaging volumes and a return to profitability, while narrowing its full-year adjusted EBITDA outlook and reiterating revenue and adjusted earnings-per-share guidance.

RALEIGH, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, today reported results for the second quarter ended June 30, 2026, and updated its full year 2026 outlook.

RALEIGH, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, today announced it will release its second quarter 2026 financial and operational results after market close on Wednesday, August 12, 2026.

Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.

The mean of analysts' price targets for Lumexa (LMRI) points to a 44.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The consensus price target hints at a 73.3% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.